Related Experiment Video
Updated: Sep 3, 2025

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
Published on: January 7, 2019
Therapeutic Cancer Vaccines-Antigen Discovery and Adjuvant Delivery Platforms
Neftali Ortega Alarcon1, Maddy Jaramillo1, Heidi M Mansour1,2,3,4
1Skaggs Pharmaceutical Sciences Center, College of Pharmacy, The University of Arizona, Tucson, AZ 85721, USA.
Abstract:
For decades, vaccines have played a significant role in protecting public and personal health against infectious diseases and proved their great potential in battling cancers as well. This review focused on the current progress of therapeutic subunit vaccines for cancer immunotherapy. Antigens and adjuvants are key components of vaccine formulations. We summarized several classes of tumor antigens and bioinformatic approaches of identification of tumor neoantigens. Pattern recognition receptor (PRR)-targeting adjuvants and their targeted delivery platforms have been extensively discussed. In addition, we emphasized the interplay between multiple adjuvants and their combined delivery for cancer immunotherapy.
Insights
Therapeutic subunit vaccines show promise for cancer immunotherapy by utilizing tumor antigens and pattern recognition receptor (PRR)-targeting adjuvants. Combining multiple adjuvants enhances their effectiveness in cancer treatment.
Area of Science:
- Immunology
- Oncology
- Vaccinology
Background:
- Vaccines are crucial for infectious disease prevention and show potential in cancer treatment.
- Therapeutic subunit vaccines represent a key strategy in cancer immunotherapy.
Purpose of the Study:
- To review the progress of therapeutic subunit vaccines for cancer immunotherapy.
- To summarize tumor antigens, neoantigen identification, and adjuvant strategies.
Main Methods:
- Literature review focusing on therapeutic subunit vaccines for cancer.
- Summarization of tumor antigen classes and bioinformatic neoantigen identification.
- Discussion of pattern recognition receptor (PRR)-targeting adjuvants and delivery platforms.
Main Results:
- Several classes of tumor antigens and methods for neoantigen identification were summarized.
- Pattern recognition receptor (PRR)-targeting adjuvants and their delivery systems were discussed.
- The importance of combining multiple adjuvants for enhanced cancer immunotherapy was highlighted.
Conclusions:
- Therapeutic subunit vaccines are advancing cancer immunotherapy.
- Strategic use of tumor antigens and PRR-targeting adjuvants is critical.
- Combined adjuvant strategies offer enhanced therapeutic potential for cancer treatment.
More Related Videos
Related Concept Videos
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Tumor Immunotherapy
Targeted Cancer Therapies
There are several types of targeted therapies against...
Microorganisms in Medicine and Therapeutics
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

